BIOmarkers of Dyspnea IN Emergency Room
- Conditions
- CAPDAcute Heart FailurePulmonary EmbolismSevere DyspneaAE COPD
- Interventions
- Other: Prognostic value of Biomarkers
- Registration Number
- NCT01227317
- Lead Sponsor
- ThermoFisher Scientific Brahms Biomarkers France
- Brief Summary
The purpose of this study is to evaluate the capacity of some novels biomarkers Procalcitonin (PCT), Midregional Proadrenomedullin (MR pro ADM), Midregional pro-atrial natriuretic peptide (MR pro ANP), Copeptin (CT pro arginine vasopressin), Pro endothelin to stratify the risk in severe dyspnea.
- Detailed Description
In emergency department shortness of breath (SOB)is a common symptom and its cause is not easy to be identified. The risk stratifying remains a challenge, Prognostic value of biomarkers might be helpful.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 444
- tachypnea > 25 /min or Pa02 < 70 mmHg or SpO2 < 93%
- diagnosis suspected: CAP, PE,EACOPD, AHF
- other cause of dyspnea,
- unreachable on Day 30
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Acute dyspnea in ED Prognostic value of Biomarkers Acute severe shortness of breath (SOB) in emergency Department (ED) with suspicion of acute heart failure (AHF) or Pulmonary Embolism (PE)or Community-acquired pneumonia (CAP) or acute Exacerbation of chronic obstructive pulmonary disease (AE COPD)
- Primary Outcome Measures
Name Time Method prognostic value of PCT, MR proADM, Mr pro ANP, Copeptin and pro endothelin in SOB at Day 30 all cause mortality or Intensive Care Unit(ICU) admission from inclusion to Day 30
- Secondary Outcome Measures
Name Time Method establish the diagnostic value of PCT and MR pro ANP at admission Confirm the diagnostic value of PCT and it's level in sepsis and MR pro ANP in Heart failure
Trial Locations
- Locations (1)
Emergency department of Pitié Salpetriere Hospital
🇫🇷Paris, France